文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

前列腺癌筛查：我们能从随机试验中学到什么？

Prostate cancer screening: what can we learn from randomised trials?

作者信息

Auvinen Anssi

机构信息

Faculty of Social Sciences/Health Sciences, University of Tampere, Tampere, Finland.

出版信息

Transl Androl Urol. 2018 Feb;7(1):12-17. doi: 10.21037/tau.2017.12.13.

DOI:10.21037/tau.2017.12.13
PMID:29594015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5861281/
Abstract

In this article, the principle of randomised trials are first described and then prostate cancer screening trials published to date are evaluated based on these principles. A summary of the randomised prostate cancer screening is provided. The conclusion that can be made from the results of the screening trials, as well as limitations of the evidence and open questions are outlined in the end.

摘要

在本文中，首先描述了随机试验的原则，然后根据这些原则对迄今为止发表的前列腺癌筛查试验进行评估。提供了随机前列腺癌筛查的总结。最后概述了从筛查试验结果中可以得出的结论，以及证据的局限性和未解决的问题。

相似文献

[1]
Prostate cancer screening: what can we learn from randomised trials?

Transl Androl Urol. 2018-2

[2]
Screening for prostate cancer.

Cochrane Database Syst Rev. 2006-7-19

[3]
Screening for prostate cancer: a Cochrane systematic review.

Cancer Causes Control. 2007-4

[4]
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.

PLoS One. 2019-11-5

[5]
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.

Eur J Cancer. 1999-2

[6]
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.

Eur Urol Focus. 2017-8-10

[7]
Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial.

Eur J Cancer. 2001-11

[8]
The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

Health Technol Assess. 2015-10

[9]
[The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].

Ned Tijdschr Geneeskd. 2005-4-30

[10]
Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.

Recent Results Cancer Res. 2014

引用本文的文献

[1]
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.

PLoS One. 2019-11-5

本文引用的文献

[1]
The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

Cancer. 2017-12-6

[2]
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Ann Intern Med. 2017-10-3

[3]
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.

Eur J Epidemiol. 2017-7-31

[4]
Equipoise in Research: Integrating Ethics and Science in Human Research.

JAMA. 2017-2-7

[5]
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.

J Urol. 2017-1-16

[6]
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Cancer. 2017-2-15

[7]
What explains the differences between centres in the European screening trial? A simulation study.

Cancer Epidemiol. 2017-2

[8]
Impact of cause of death adjudication on the results of the European prostate cancer screening trial.

Br J Cancer. 2017-1-3

[9]
Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies.

PLoS One. 2016-7-11

[10]
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.

Oncologist. 2016-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索